Stocks · News reference

NervGen Doses First Participant In Phase 3 RESTORE Study Of NVG-291 For Chronic Cervical SCI; Enrollment Completion Expected In H2 2027, Topline Data In H1 2028

Oct 12, 2026, 11:17 AMBenzinga Newsdesk

RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injuryStudy builds on functional improvements observed in

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NGEN

Source: benzinga
Observed: Oct 12, 2026, 11:17 AM
Checked: Oct 12, 2026, 11:17 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 25, 2026, 8:34 PMBenzinga Newsdesk
NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026
Adjustments have no impact on cash and cash equivalents, cash runway, or business operations.Restatement is expected to reduce previously reported stock-based compensation expense, warrant liabilities, and accumulated
NGEN

NervGen Doses First Participant In Phase 3 RESTORE Study Of NVG-291 For Chronic Cervical SCI; Enrollment Completion Expected In H2 2027, Topline Data In H1 2028

Connected Markets

Related Headlines

NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026